Researchers uncover 'hidden key' to immunotherapy for intractable brain tumors. Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" exploited by tumors to evade attack—show limited efficacy in some brain tumors.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" exploited by tumors to evade attack—show limited efficacy in some brain tumors. A KAIST research team found that B-cell and antibody responses initiated in tumor-draining lymph nodes, rather than T cells alone, are critical to the antitumor effects of anti-CTLA-4 therapy, opening a new avenue for treating intractable brain tumors.
- Ponto de atenção: researchers.
- Ponto de atenção: uncover.
- Ponto de atenção: hidden.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Saúde.
:quality(85)/669618b1-141a-4921-9772-711b308e2cf3.jpeg)
:quality(85)/b5f66200-d105-4d8b-8d08-0a1d9d4283b4.jpeg)
:quality(85)/5fde977d-4945-4e5f-8960-f3ef3d0edfa7.webp)